Expression and clinical significance of non-phagocytic cell oxidase 2 and 4 after human traumatic brain injury

2014 ◽  
Vol 36 (1) ◽  
pp. 61-71 ◽  
Author(s):  
Zhen Li ◽  
Fengxuan Tian ◽  
Zhong Shao ◽  
Xuming Shen ◽  
Xin Qi ◽  
...  
2014 ◽  
Vol 80 (3) ◽  
pp. 310-312 ◽  
Author(s):  
Cherisse Berry ◽  
Eric J. Ley ◽  
Daniel R. Margulies ◽  
Jessica Pruett ◽  
Chad Miller ◽  
...  

2017 ◽  
Vol 83 (4) ◽  
pp. 725-731 ◽  
Author(s):  
Farshad Nassiri ◽  
Jetan H. Badhiwala ◽  
Christopher D. Witiw ◽  
Alireza Mansouri ◽  
Benjamin Davidson ◽  
...  

1998 ◽  
Vol 15 (4) ◽  
pp. 253-263 ◽  
Author(s):  
JENNIFER I.M. BROWN ◽  
ANDREW J. BAKER ◽  
STEFAN J. KONASIEWICZ ◽  
RICHARD J. MOULTON

Author(s):  
Alexander Fletcher-Sandersjöö ◽  
Charles Tatter ◽  
Jonathan Tjerkaski ◽  
Jiri Bartek Jr ◽  
Mikael Svensson ◽  
...  

AbstractPreventing hemorrhage progression is a potential therapeutic opportunity in traumatic brain injury (TBI) management, but its use has been limited by fear of provoking vascular occlusive events (VOEs). However, it is currently unclear whether VOE actually affects outcome in these patients. The aim of this study was to determine incidence, risk factors, and clinical significance of VOE in patients with moderate-to-severe TBI. A retrospective observational cohort study of adults (≥15 years) with moderate-to-severe TBI was performed. The presence of a VOE during hospitalization was noted from hospital charts and radiological reports. Functional outcome, using the Glasgow Outcome Scale (GOS), was assessed at 12 months posttrauma. Univariate and multivariate logistic regressions were used for endpoint assessment. In total, 848 patients were included, with a median admission Glasgow Coma Scale of 7. A VOE was detected in 54 (6.4%) patients, of which cerebral venous thrombosis was the most common (3.2%), followed by pulmonary embolism (1.7%) and deep vein thrombosis (1.3%). Length of ICU stay (p < 0.001), body weight (p = 0.002), and skull fracture (p = 0.004) were independent predictors of VOE. VOE development did not significantly impact 12-month GOS, even after adjusting for potential confounders using propensity score matching. In conclusion, VOE in moderate-to-severe TBI patients was relatively uncommon, and did not affect 12-month GOS. This suggests that the potential benefit of treating bleeding progression might outweigh the risks of VOE.


Brain Injury ◽  
2006 ◽  
Vol 20 (1) ◽  
pp. 15-21 ◽  
Author(s):  
Matilde Inglese ◽  
Robert I. Grossman ◽  
Leonard Diller ◽  
James S. Babb ◽  
Oded Gonen ◽  
...  

2021 ◽  
Vol 7 (4) ◽  
pp. 264-273
Author(s):  
He Wang ◽  
Kaili Liu ◽  
Chao Xiu ◽  
Bin Liu ◽  
Wantao Zhao ◽  
...  

Traumatic brain injury (TBI) is becoming the main cause of death threatening human life because of its high disability rate, high mortality rate and great social harm. The purpose of this study was to investigate the dynamic changes and clinical significance of leukocytes (WBC) and platelets (PLT) in patients with traumatic brain injury. In the process of specimen collection, 4ml of peripheral venous blood was collected 24 hours, 4 days, 7 days, 14 days and 21 days after craniocerebral injury using sterile, non-heat source and non-endotoxin test tube. 2ml venous blood was added into EDTA anticoagulant blood collection vessel to detect the changes of peripheral blood leukocytes and platelets in patients with craniocerebral injury. In addition, 2 ml venous blood was added into the procoagulant blood collection vessel, and the serum was separated and frozen for the determination of CRP and TSP1. All patients were evaluated with Glasgow outcome score at discharge. When detecting PLT and WBC, Sysmex K4500 hematology analyzer was used to routinely measure the number of PLT and WBC in peripheral blood at different time points. In the process of CRP (C- reactive protein) measurement, adjust the pipette to 60 μ l, and add 50 μl of developer a and developer B into the micropore respectively. Then it vibrates on a mini vibrator for 5 seconds to ensure mixing. Preheat the microplate reader for 30 minutes, place the microplate in the microplate reader, set the parameters and read the values. When measuring TSP1 (thrombin sensitive protein 1), adjust the micro pipette to 50 μ l, then add 50μl termination solution into the micropore respectively, and then vibrate on the micro vibrator for 30 seconds to ensure full mixing. Further analysis showed that there was no difference between the non-infection group and the normal control group on the 4th day (P > 0.05). This study is helpful to the timely treatment of patients with traumatic brain injury.


Sign in / Sign up

Export Citation Format

Share Document